Establishment Labs (ESTA) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
10 Apr, 2026Executive summary
Annual meeting scheduled for May 22, 2026, with voting available online or virtually at 1:00 PM ET.
Shareholders are encouraged to review proxy materials and vote on key proposals by May 21, 2026.
Voting matters and shareholder proposals
Election of six directors for a one-year term, with all nominees recommended by the board.
Advisory vote to approve executive compensation for named executive officers.
Ratification of CBIZ CPAS P.C. as the independent registered public accounting firm for fiscal year ending December 31, 2026.
Board of directors and corporate governance
Six director nominees listed: Filippo "Peter" Caldini, Ann Custin, Leslie Gillin, Nicholas Lewin, Edward Schutter, and Bryan Slotkin.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Establishment Labs
- Virtual meeting to elect directors, approve pay, and ratify auditor, with strong governance focus.ESTA
Proxy filing10 Apr 2026 - Q4 revenue up 45%, gross margin at 70.5%, and 2026 guidance projects 25%+ growth.ESTA
Q4 20259 Apr 2026 - Motiva's U.S. growth outpaced expectations, with premium pricing and innovation fueling expansion.ESTA
TD Cowen 46th Annual Health Care Conference2 Mar 2026 - Q2 revenue rose 18.7% sequentially; FDA approval for Motiva Implants expected soon.ESTA
Q2 20242 Feb 2026 - Innovation, global expansion, and regulatory progress position the company for rapid growth.ESTA
Goldman Sachs 45th Annual Global Healthcare Conference1 Feb 2026 - U.S. approval nears as global expansion and premium product launches drive margin growth.ESTA
Jefferies Global Healthcare Conference31 Jan 2026 - US market share surges with FDA-approved, innovative implants and strong financial momentum.ESTA
44th Annual J.P. Morgan Healthcare Conference30 Jan 2026 - Q3 revenue grew, losses narrowed, and U.S. Motiva launch plus new funding boosted outlook.ESTA
Q3 202415 Jan 2026 - FDA approval and U.S. launch drive growth outlook, with 2025 set as a transformative year.ESTA
UBS Global Healthcare Conference14 Jan 2026